Medical Device Sterilization Residue Analysis: Standards, Testing Items, and Analytical Methods

Sterilization residue analysis is an essential chemical safety evaluation for medical devices sterilized with ethylene oxide, formaldehyde, hydrogen peroxide, and other sterilizing agents, ensuring that residual chemicals remain within biologically safe limits before product release. This technical article explains the regulatory framework, typical sample types, testing items, analytical methods, and practical considerations for sterilization residue testing performed by accredited third-party laboratories.

Technical Overview

Sterilization residue analysis refers to the quantitative determination of residual sterilants and their reaction by-products that remain on or within a medical device after a sterilization and aeration cycle. Because many low-temperature sterilization processes rely on chemically reactive agents, measurable quantities of these substances can remain in device materials, adhesives, and packaging after processing, and may subsequently be released to the patient during clinical use.

The most extensively regulated residue scenario involves ethylene oxide (EO) sterilization, which can leave residues of EO itself along with its reaction products ethylene chlorohydrin (ECH) and, historically, ethylene glycol (EG). EO is classified as a genotoxic and carcinogenic irritant, while ECH is a recognized systemic toxicant, which is why their residual levels are strictly controlled. Other sterilization technologies generate their own residue concerns, including formaldehyde from low-temperature steam formaldehyde (LTSF) sterilization, hydrogen peroxide from vaporized or plasma-based processes, and peracetic acid or chlorine dioxide from liquid and gaseous alternative processes.

The primary international standard governing this field is ISO 10993-7, which defines tolerable contact limits for EO and ECH, extraction procedures, and calculation methods for the device-delivered dose to the patient. It is supported by ISO 10993-12 for sample preparation, ISO 10993-17 for the establishment of allowable limits, and ISO 11135 for EO sterilization process validation, including aeration. In the Chinese regulatory framework, the equivalent standard is GB/T 16886.7. For LTSF processes, EN 14180 and ISO 25424 provide relevant sterilizer and process requirements. Manufacturers typically support regulatory submissions, batch release, and aeration validation with residue data generated under an ISO/IEC 17025-accredited quality system in accredited third-party laboratories.

Testing Samples

Ethylene Oxide Sterilized Single-Use Devices

This is the largest sample category and includes disposable syringes, intravenous catheters and infusion sets, urinary catheters, wound dressings, absorbable and non-absorbable sutures, tracheal tubes, dialysis consumables, surgical drapes and gowns, and complete procedure kits. Polymeric materials, cellulose-based products, and multi-component kits tend to absorb and retain more EO, so sample selection must represent the worst-case product configuration.

Hydrogen Peroxide and Plasma Sterilized Products

Devices processed in vaporized hydrogen peroxide or hydrogen peroxide gas plasma systems, including heat- and moisture-sensitive instruments, rigid endoscope components, and reusable accessories, are evaluated for residual peroxide after repeated cycles.

Low-Temperature Steam Formaldehyde Sterilized Products

Products processed in LTSF sterilizers are tested for residual formaldehyde, with attention to porous materials and lumened devices where condensate residues may accumulate.

Implantable and Long-Term Contact Devices

Implants, central venous catheters, dialyzers, blood oxygenators, and other prolonged or permanent-contact devices require the most conservative evaluation because patient exposure extends beyond 24 hours or 30 days, and special limits may apply to devices such as intraocular lenses and blood-contacting devices as defined in ISO 10993-7.

Sampling and Handling Requirements

• Samples should be drawn from worst-case load positions, such as the load center, cold spot, or locations adjacent to chamber walls and the door.
• Primary packaging must remain hermetically sealed after sterilization to prevent further EO off-gassing during transport and storage.
• The elapsed time between sterilization, aeration completion, and sample receipt must be documented, because residues decline continuously during aeration.
• Replicate analytical samples, typically triplicate sets per time point or condition, are required to support statistical evaluation.
• Transport under controlled temperature conditions with chain-of-custody documentation.

Testing Items

Testing items are selected according to the sterilization process, device contact category, and exposure duration defined by the biological evaluation plan.

• Ethylene oxide (EO) residual content, reported in micrograms per device or micrograms per gram.
• Ethylene chlorohydrin (ECH) residual content.
• Ethylene glycol (EG) residual content, included where required by risk assessment or legacy submissions.
• Formaldehyde residuals for LTSF sterilized products.
• Hydrogen peroxide residuals for vapor or plasma sterilized products.
• Peracetic acid and chlorine dioxide residuals where these agents are used.
• Residual decline (aeration kinetics) studies at multiple post-sterilization time points to establish product release time.

Testing Methods

Extraction and Sample Preparation

ISO 10993-7 defines two principal extraction concepts. Simulated-use extraction, often performed in water at 37 °C for one hour, reproduces the clinical extraction conditions and is used for routine release testing of most devices. Exhaustive extraction, in which the device is extracted repeatedly until the residue recovered in subsequent extractions falls below a defined fraction of the first extraction, provides a conservative worst-case estimate and is applied to implants, devices with prolonged contact, or where simulated use is not representative. Sample preparation also follows ISO 10993-12 principles, and both individual device results and composite kit results may be required.

Determination of EO and ECH by Gas Chromatography

Headspace gas chromatography with flame ionization detection (HS-GC-FID) is the reference technique for EO and ECH. Aliquots of the aqueous extract are sealed in headspace vials, equilibrated at elevated temperature to partition volatile residues into the headspace, and analyzed on suitable capillary columns against certified calibration standards. GC-MS is used where confirmation of identity or enhanced selectivity is needed. Validated methods typically achieve detection limits well below the applicable specification limits.

Determination of Other Sterilant Residues

• Formaldehyde is commonly determined by HPLC-UV after derivatization with 2,4-dinitrophenylhydrazine, or by acetylacetone spectrophotometry.
• Hydrogen peroxide is measured by validated enzymatic or titanium-based colorimetric methods or by ion chromatography.
• Ethylene glycol, where tested, is determined by derivatization followed by gas chromatography or by HPLC with refractive index detection.

Data Evaluation Against Tolerable Limits

Measured concentrations are converted into the device-delivered dose in milligrams per device or per patient, then compared with the tolerable contact limits of ISO 10993-7. For limited-exposure devices with patient contact up to 24 hours, the limits are 4 mg for EO and 9 mg for ECH; for prolonged-exposure devices with contact between 24 hours and 30 days, the limits are 60 mg for EO and 138 mg for ECH, with additional constraints on daily dose. Permanent-contact devices and small-body-mass patients require the adjustment procedures described in the standard.

Quality Assurance and Method Validation

Residue methods are validated for linearity, accuracy, precision, recovery, and limits of detection and quantification in accordance with the laboratory quality system, and testing is performed within an ISO/IEC 17025-accredited environment to ensure data integrity and global regulatory acceptability.

Applications

Sterilization residue analysis supports manufacturers throughout the product lifecycle and regulatory process.

• Validation of EO sterilization cycles, including aeration confirmation, in conjunction with ISO 11135 performance qualification.
• Routine batch release testing and parametric or dosimetric release justification.
• Regulatory submissions for market authorization across jurisdictions requiring ISO 10993-7 or GB/T 16886.7 data.
• Product and packaging development, including material selection and aeration cycle optimization.
• Investigation of out-of-specification results, customer complaints, and change control for materials or process parameters.
• Residual decline studies used to define the minimum quarantine or aeration time before product release.

FAQ

What are the ISO 10993-7 limits for EO and ECH residues?

For devices with limited patient contact of up to 24 hours, the maximum device-delivered doses are 4 mg of EO and 9 mg of ECH. For prolonged contact of 24 hours to 30 days, the limits are 60 mg of EO and 138 mg of ECH. Permanent-contact devices, small patients, and special device types such as intraocular lenses are evaluated using the adjustment procedures given in the standard.

When should residue testing be performed after sterilization?

Because residues decline continuously during aeration, testing should reflect the worst case, namely the earliest time point at which the product may be released. A residual decline study with multiple post-sterilization time points can be used to model the decrease and justify the release time.

Should simulated-use or exhaustive extraction be used?

Simulated-use extraction is appropriate for routine evaluation of most devices because it reflects clinical exposure. Exhaustive extraction is applied to implants and long-term contact devices, or whenever a conservative worst-case assessment is required. The choice must be justified in the test protocol.

Is ethylene glycol testing still required?

Since the 2008 revision of ISO 10993-7, EG evaluation is generally not required when EO and ECH results comply with the applicable limits. EG may still be included based on a risk assessment or specific regulatory expectations.

How are multi-device procedure kits evaluated?

All devices within a kit contribute to the total patient dose, so residue data must support the summed device-delivered dose for the entire kit rather than a single component.

What sample quantities and turnaround times are typical?

Requirements depend on the device, extraction mode, and number of time points, and are defined in the test plan. Most routine EO and ECH determinations by headspace GC can be completed within one to two weeks, while full decline studies are scheduled across the designated aeration period.